Drug development is governed by an alphabet soup of quality standards. The three most fundamental — GLP, GMP, and GCP — apply to different stages and have different requirements. Mixing them up is a common rookie mistake.
GLP: Good Laboratory Practice
Scope: Nonclinical (preclinical) safety studies — typically toxicology and safety pharmacology — that support regulatory submissions.
Regulatory basis: 21 CFR Part 58 (US), OECD GLP Principles (international).
Key requirements:
- Detailed study protocols approved before initiation
- Designated study director responsible for overall conduct
- Documented training and qualification of personnel
- Calibrated, qualified equipment with maintenance records
- Defined SOPs for all study activities
- Quality Assurance Unit independent of study conduct
- Comprehensive raw data records and final study reports
- Archival of records for defined retention periods
Common misconception: “GLP” does not apply to discovery or efficacy studies — only to safety studies submitted to regulators.
GMP: Good Manufacturing Practice
Scope: Manufacturing of drug products and active pharmaceutical ingredients (APIs).
Regulatory basis: 21 CFR Parts 210/211 (US), EU GMP guidelines, ICH Q7.
Key requirements:
- Defined Quality Management System
- Validated manufacturing processes
- Qualified facilities and equipment
- Defined material specifications and testing
- Batch records documenting every manufacturing step
- Stability programs supporting expiration dating
- Trained personnel
- Deviation, change control, and CAPA systems
- Quality release of every batch by a Qualified Person (EU) or designated Quality unit
GMP applies in increasing rigor across the drug lifecycle: less stringent for early clinical materials (Phase I), more stringent for Phase III and commercial manufacturing.
GCP: Good Clinical Practice
Scope: Clinical trials in human subjects.
Regulatory basis: ICH E6(R3), 21 CFR Parts 50/56/312 (US).
Key requirements:
- IRB/Ethics Committee approval before enrolling subjects
- Informed consent process
- Trained, qualified investigators
- Detailed protocol followed without unauthorized deviation
- Source documentation and accurate data capture
- Pharmacovigilance and safety reporting
- Sponsor oversight (monitoring, audits)
- Investigational product accountability
- Trial Master File documenting all activities
Summary comparison
| Standard | Stage | Focus | Inspector |
|---|---|---|---|
| GLP | Preclinical safety | Reproducibility of safety data | FDA, EPA, MHRA |
| GMP | Manufacturing | Product quality and consistency | FDA, EMA, MHRA |
| GCP | Clinical trials | Subject protection and data integrity | FDA, EMA, IRB |
How they fit together
A typical drug program starts with non-GLP discovery work, transitions to GLP-compliant pivotal toxicology, requires GMP-grade material for clinical trials, and conducts those trials under GCP. As the program advances, regulatory expectations tighten.
Other related standards
- GVP: Good Pharmacovigilance Practice — post-marketing safety monitoring
- GDP: Good Distribution Practice — drug product storage and shipping
- GTP / GCTP: Good Tissue Practice / Good Cell and Tissue Practice — for cell and gene therapies
- 21 CFR Part 11: Electronic records and signatures (US)
Inspections
Regulatory agencies inspect for compliance:
- GLP inspections focus on protocol adherence, raw data integrity, and QA oversight
- GMP inspections focus on manufacturing controls, validation, change control, and product testing
- GCP inspections focus on informed consent, source data verification, deviations, and adverse event reporting
Practical tips for compliance
- Document everything contemporaneously — “if it isn’t documented, it didn’t happen”
- Train all personnel on relevant SOPs and document the training
- Maintain change control records for protocol amendments
- Keep raw data legible, attributable, and traceable
- Use validated systems for electronic data capture
- Independent QA review at defined milestones
GLP, GMP, and GCP exist to make drug development data trustworthy. Following them isn’t bureaucratic theater — it’s the foundation that lets regulators, doctors, and patients trust the drugs that emerge.
